Intravenous Immunoglobulin Therapy in Guillain-Barre Syndrome
Journal of the Korean Neurological Association
;
: 709-714, 1994.
Artigo
em Coreano
| WPRIM
| ID: wpr-49787
ABSTRACT
High dose intravenous immunoglobulin (IVIg) therapy can improve the clinical course of several immune mediciated diseases. We evaluated clinical effects and side effects of IVIg in Guillain-Barre syndrome (GBS). 19 Patients with GBS were studied prospectively in a placebo-controlled trial. 11 Patients were received high dose IVIg (400mg/kg for 5 days) and controls received only conservative treatment. The disability scores using modified Rankin scores before and after treatment of each group were compared. Four weaks later, mean Rankin Score of IVIg group was 2.5 + 0.7 and control group was 3.3+ 0.5which showed significant difference(p<0.05). There were no serious advers effer of promote early improvement with safety in acute phase of Guillan-Barre syndrome.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Imunoglobulinas
/
Estudos Prospectivos
/
Imunização Passiva
/
Imunoglobulinas Intravenosas
/
Síndrome de Guillain-Barré
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo observacional
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Neurological Association
Ano de publicação:
1994
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS